US2010008948A1PendingUtilityA1

Recombinant herpesvirus useful in vaccine production

67
Assignee: SCHERING PLOUGH ANIMAL HEALTHPriority: Jun 14, 2001Filed: Aug 11, 2009Published: Jan 14, 2010
Est. expiryJun 14, 2021(expired)· nominal 20-yr term from priority
Inventors:Mark D. CochranStephanie CookMatha A. Wild
C12N 2710/16334A61K 2039/5256A61K 39/12C12N 2760/18134C12N 7/00C12N 2710/16343C12N 15/86A61P 31/12A61K 2039/70A61P 31/22A61K 2039/552
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides a novel avian herpesvirus (NAHV) vector and recombinant vaccines made therefrom that are useful to immunize avian species against Marek's disease, infectious laryngotracheitis and Newcastle disease. Methods of immunizing an avian species against Marek's disease, infectious laryngotracheitis and Newcastle disease are also provided.

Claims

exact text as granted — not AI-modified
1 . A recombinant avian herpesvirus comprising a herpes virus of turkeys unique long and repeat viral genome region and a Marek's disease virus unique short viral genome region wherein at least one foreign DNA sequence is inserted within a US2 gene of the unique short region of the recombinant avian herpesvirus and is capable of being expressed in a host cell. 
     
     
         2 . The recombinant avian herpesvirus of  claim 1  wherein the foreign DNA sequence is selected from the group consisting of: a Newcastle disease virus fusion gene, an infectious laryngotracheitis virus glycoprotein D gene, or an infectious laryngotracheitis glycoprotein I gene. 
     
     
         3 . The recombinant avian herpesvirus of  claim 2  wherein the foreign DNA sequence is the Newcastle disease virus fusion gene. 
     
     
         4 . The recombinant avian herpesvirus of  claim 3  designated NAHV/NDV 295-93 (ATCC Accession number VR______). 
     
     
         5 . The recombinant avian herpesvirus of  claim 2  wherein the foreign DNA sequence is the infectious laryngotracheitis virus glycoprotein D gene. 
     
     
         6 . The recombinant avian herpesvirus of  claim 2  wherein the foreign DNA sequence is the infectious laryngotracheitis virus glycoprotein I gene. 
     
     
         7 . The recombinant avian herpesvirus of  claim 2  wherein the foreign DNA sequences are the infectious laryngotracheitis virus glycoprotein D gene and the infectious laryngotracheitis virus glycoprotein I gene. 
     
     
         8 . The recombinant avian herpesvirus of  claim 7  designated NAHV/ILT 295-149 (ATCC Accession number VR______). 
     
     
         9 . The recombinant avian herpesvirus of  claim 2  wherein the foreign DNA sequences are the Newcastle disease virus fusion gene, the infectious laryngotracheitis virus glycoprotein D gene and the infectious laryngotracheitis virus glycoprotein I gene. 
     
     
         10 . The recombinant avian herpesvirus designated NAHV 295-01 (ATCC Accession number VR______). 
     
     
         11 . A vaccine for protecting against Newcastle disease comprising an effective immunizing amount of the recombinant avian herpesvirus of  claim 3  and a suitable carrier. 
     
     
         12 . A vaccine for protecting against Newcastle disease comprising an effective immunizing amount of the recombinant avian herpesvirus of  claim 4  and a suitable carrier. 
     
     
         13 . A vaccine for protecting against infectious laryngotracheitis comprising an effective immunizing amount of the recombinant avian herpesvirus of  claim 7  and a suitable carrier. 
     
     
         14 . A vaccine for protecting against infectious laryngotracheitis comprising an effective immunizing amount of the recombinant avian herpesvirus of  claim 8  and a suitable carrier. 
     
     
         15 . A vaccine for protecting against Marek's disease comprising an effective immunizing amount of the recombinant avian herpesvirus of  claim 10 . 
     
     
         16 . A multivalent vaccine for protecting against Marek's disease, infectious laryngotracheitis and Newcastle disease comprising an effective immunizing amount of the recombinant avian herpesvirus of  claim 9  and a suitable carrier. 
     
     
         17 . A multivalent vaccine for protecting against Marek's disease, infectious laryngotracheitis and Newcastle disease comprising, as a mixture, an effective immunizing amount of a first recombinant avian herpesvirus, designated NAHV/ILT 295-149 (ATCC Accession number VR______), an effective immunizing amount of a second recombinant avian herpesvirus, designated NAHV/NDV 295-93 (ATCC Accession number VR______), and a suitable carrier. 
     
     
         18 . A method of immunizing an avian species against Newcastle disease comprising administering to the avian species an effective immunizing amount of the vaccine of  claim 11 . 
     
     
         19 . A method of immunizing an avian species against Newcastle disease comprising administering to the avian species an effective immunizing amount of the vaccine of  claim 12 . 
     
     
         20 . A method of immunizing an avian species against infectious laryngotracheitis comprising administering to the avian species an effective immunizing amount of the vaccine of  claim 13 . 
     
     
         21 . A method of immunizing an avian species against infectious laryngotracheitis comprising administering to the avian species an effective immunizing amount of the vaccine of  claim 14 . 
     
     
         22 . A method of immunizing an avian species against Marek's disease comprising administering to the avian species an effective immunizing amount of the vaccine of vaccine of  claim 15 . 
     
     
         23 . A method of immunizing an avian species against Marek's disease, infectious laryngotracheitis and Newcastle disease comprising administering to the avian species an effective immunizing amount of the vaccine of  claim 16 . 
     
     
         24 . The vaccine as in  claim 11  wherein the suitable carrier is a physiologically balanced culture medium containing stabilizing agents. 
     
     
         25 . The vaccine as in  claim 13  wherein the suitable carrier is a physiologically balanced culture medium containing stabilizing agents. 
     
     
         26 . The vaccine as in  claim 15  wherein the suitable carrier is a physiologically balanced culture medium containing stabilizing agents. 
     
     
         27 . The vaccine as in  claim 16  wherein the suitable carrier is a physiologically balanced culture medium containing stabilizing agents. 
     
     
         28 . The method of  claim 18 , wherein the vaccine is administered by injection. 
     
     
         29 . The method of  claim 20 , wherein the vaccine is administered by injection. 
     
     
         30 . The method of  claim 22 , wherein the vaccine is administered by injection. 
     
     
         31 . The method of  claim 23 , wherein the vaccine is administered by injection. 
     
     
         32 . The method of  claim 18 , wherein the vaccine is administered intraocularly. 
     
     
         33 . The method of  claim 20 , wherein the vaccine is administered intraocularly. 
     
     
         34 . The method of  claim 22 , wherein the vaccine is administered intraocularly. 
     
     
         35 . The method of  claim 23 , wherein the vaccine is administered intraocularly. 
     
     
         36 . The method of  claim 18 , wherein the vaccine is administered orally. 
     
     
         37 . The method of  claim 20 , wherein the vaccine is administered orally. 
     
     
         38 . The method of  claim 22 , wherein the vaccine is administered orally. 
     
     
         39 . The method of  claim 23 , wherein the vaccine is administered orally.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.